Sign Up Today and Learn More About Myeloid Therapeutics Stock
Invest in or calculate the value of your shares in Myeloid Therapeutics or other pre-IPO companies through EquityZen's platform.
Myeloid Therapeutics Stock
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases.
About Myeloid Therapeutics Stock
Founded
2019
Headquarters
Cambridge, MA, US
Industries
Myeloid Therapeutics Press Mentions
Stay in the know about the latest news on Myeloid Therapeutics
Myeloid Therapeutics to Participate in the Jefferies Healthcare Conference Private Biotech Day
prnewswire • Jul 05, 2024
Myeloid Therapeutics to Participate in the Jefferies Healthcare Conference Private Biotech Day
wboy • Jun 04, 2024
Myeloid to run$96m Australian RNA facility - BioProcess Insider
bioprocessintl • Jun 04, 2024
Myeloid Therapeutics Presents Multiple Posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual ...
prnewswire • Jun 04, 2024
Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR
prnewswire • May 23, 2024
Myeloid Therapeutics Management
Leadership team at Myeloid Therapeutics
Chief Executive Officer & Co-Founder
Daniel Getts
Co-founder & Snr. Director, Discovery Research
Yuxiao Wang
Join now and verify your accreditation status to gain access to:
- Myeloid Therapeutics current valuation
- Myeloid Therapeutics stock price
- Available deals in Myeloid Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Myeloid Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Myeloid Therapeutics through EquityZen funds. These investments are made available by existing Myeloid Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Myeloid Therapeutics stock?
Shareholders can sell their Myeloid Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
